TrialPath
← Back to searchRecruiting

Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis

NCT06318598 · Istituto Auxologico Italiano
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Dissezione Fenotipica Guidata da Biomarcatori Della Sclerosi Laterale Amiotrofica/Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis
About this study
The goal of this observational study is to understand the clinical variability in a population of ALS patients using multidimensional biomarkers. The main questions it aims to answer are: * Which set of biomarkers explain genotypic-phenotypic correlations in ALS? * Which set of biomarkers can be used to subdivide the ALS population in homogeneous subgroups? Participants will undergo: * neurological evaluation * neurophysiological evaluation * neuropsychological evaluation * whole exome sequencing * biomarker measurement in CSF and plasma
Eligibility criteria
Inclusion Criteria: * diagnosis of ALS or other motor neuron disease * residence near the study centers Exclusion Criteria: * refusal to participate to the study * unable/unwilling to perform follow-up visits
Study design
Enrollment target: 200 participants
Age groups: adult, older_adult
Timeline
Starts: 2023-04-11
Estimated completion: 2026-04-10
Last updated: 2025-05-07
Primary outcomes
  • genetic screening (baseline (at diagnosis))
  • biomarker assessment (baseline (at diagnosis), at 6 months, at 1 year)
Sponsor
Istituto Auxologico Italiano · other
With: A.O.U. Città della Salute e della Scienza, Ospedale San Raffaele
Contacts & investigators
ContactNicola Ticozzi, MD, PhD · contact · n.ticozzi@auxologico.it · +390261911
All locations (3)
Ospedale San RaffaeleRecruiting
Milan, MI, Italy
Ospedale San LucaRecruiting
Milan, MI, Italy
AOU Città della Salute e della ScienzaRecruiting
Torino, TO, Italy
Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis · TrialPath